DIAN-TU Gantenerumab Open-Label Extension and Tau NexGen Trials Update

Description: An update on recent trials using gantenerumab and targeting tau in the treatment of Alzheimer’s disease
Runtime: 00:19:39

Speaker: Randall Bateman, MD
Speaker title: DIAN Trials Unit Director
Speaker organization: Washington University in St. Louis

Event: 2021 Virtual DIAD Family Conference: Beyond Abeta
Year: 2021

Search tags: DIAN history, amyloid plaques, hypometabolism, cortical atrophy, primary prevention, secondary prevention, gantenerumab, Cognitive Run-In, solanezumab, DIAN-TU-001 Trial, biomarkers, open-label extension, disease progression, combination therapy, tau PET imaging